Mark Pollack to Double-Blind Method
This is a "connection" page, showing publications Mark Pollack has written about Double-Blind Method.
Connection Strength
2.376
-
Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. CNS Spectr. 2010 Jul; 15(7):367-73.
Score: 0.329
-
Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale. Contemp Clin Trials. 2015 Jul; 43:223-30.
Score: 0.116
-
A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014 Jan; 171(1):44-53.
Score: 0.105
-
D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. J Consult Clin Psychol. 2013 Dec; 81(6):1100-12.
Score: 0.102
-
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom. 2012; 81(2):87-97.
Score: 0.092
-
Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011 Jul; 72(7):892-7.
Score: 0.086
-
Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry. 2010 May; 71(5):627-31.
Score: 0.079
-
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2010 Feb 15; 67(4):365-70.
Score: 0.078
-
Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. J Clin Psychiatry. 2009 Nov; 70(11):1563-70.
Score: 0.078
-
Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol. 2008 Jun; 28(3):308-16.
Score: 0.071
-
Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry. 2008 Mar; 69(3):400-5.
Score: 0.070
-
Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res. 2008 Oct; 42(12):1042-9.
Score: 0.070
-
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007 Oct; 194(2):233-42.
Score: 0.067
-
The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. 2007 Feb; 27(1):85-8.
Score: 0.065
-
A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007; 24(1):1-14.
Score: 0.065
-
The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry. 2005 Nov; 66(11):1401-8.
Score: 0.060
-
Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006 Feb 01; 59(3):211-5.
Score: 0.059
-
Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol. 2003 Sep; 17(3):276-82.
Score: 0.051
-
Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder. J Psychiatr Res. 2002 Jul-Aug; 36(4):229-36.
Score: 0.047
-
Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001 May; 62(5):350-7.
Score: 0.044
-
Do antidepressants selectively suppress spontaneous (unexpected) panic attacks? A replication. J Clin Psychopharmacol. 2000 Dec; 20(6):622-7.
Score: 0.042
-
Sertraline treatment of panic disorder: response in patients at risk for poor outcome. J Clin Psychiatry. 2000 Dec; 61(12):922-7.
Score: 0.042
-
Dose Timing of D-Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2020 06 01; 3(6):e206777.
Score: 0.041
-
Effect of d-cycloserine on fear extinction training in adults with social anxiety disorder. PLoS One. 2019; 14(10):e0223729.
Score: 0.039
-
Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998 Nov; 55(11):1010-6.
Score: 0.037
-
Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry. 1997; 58 Suppl 11:19-23.
Score: 0.032
-
RANDOMIZED TRIAL OF D-CYCLOSERINE ENHANCEMENT OF COGNITIVE-BEHAVIORAL THERAPY FOR PANIC DISORDER. Depress Anxiety. 2016 08; 33(8):737-45.
Score: 0.031
-
Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull. 1996; 32(4):667-70.
Score: 0.030
-
Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo. J Affect Disord. 1994 Apr; 30(4):273-81.
Score: 0.027
-
Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol. 1993 Aug; 13(4):257-63.
Score: 0.025
-
D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res. 2013 Oct; 47(10):1455-61.
Score: 0.025
-
Two weeks of pretreatment with escitalopram facilitates extinction learning in healthy individuals. Hum Psychopharmacol. 2013 Sep; 28(5):447-56.
Score: 0.025
-
D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry. 2013 Jun 01; 73(11):1054-8.
Score: 0.025
-
Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry. 2012 Mar; 73(3):353-7.
Score: 0.022
-
RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010 Oct; 16(5):322-5.
Score: 0.021
-
Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol. 2008 Aug; 23(6):519-26.
Score: 0.018
-
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006 Mar; 63(3):298-304.
Score: 0.015
-
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005 Sep; 62(9):1022-30.
Score: 0.015
-
Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005 Jan; 177(3):280-8.
Score: 0.014
-
Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004 Apr; 24(2):141-9.
Score: 0.013
-
Treatment of muscle contraction headache: Micrainin vs. aspirin. Headache. 1982 May; 22(3):101-9.
Score: 0.012
-
Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand. 2001 Oct; 104(4):289-98.
Score: 0.011
-
Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000 Aug; 20(4):467-71.
Score: 0.010
-
Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000 Jun; 157(6):968-74.
Score: 0.010
-
Is placebo response the same as drug response in panic disorder? Am J Psychiatry. 2000 Jun; 157(6):1014-6.
Score: 0.010
-
Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999 May; 156(5):756-60.
Score: 0.009
-
Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997 Aug; 17(4):247-54.
Score: 0.008
-
The relationship of alprazolam and clonazepam dose to steady-state concentration in plasma. J Clin Psychopharmacol. 1994 Aug; 14(4):274-6.
Score: 0.007
-
Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo. J Affect Disord. 1993 May; 28(1):27-38.
Score: 0.006
-
Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry. 1991 Feb; 52(2):69-76.
Score: 0.005
-
Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder. Psychiatry Res. 1989 Jun; 28(3):345-50.
Score: 0.005
-
Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial. J Clin Psychiatry. 1987 Oct; 48 Suppl:16-21.
Score: 0.004
-
A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis. J Infect Dis. 1980 May; 141(5):543-7.
Score: 0.003